View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

Cynata Therapeutics gets approval for Covid-19 clinical trial

Australia-based Cynata Therapeutics has secured ethics committee approval to conduct a clinical trial of its Cymerus mesenchymal stem cells (MSCs) to treat adult Covid-19 patients admitted to intensive care.

Called MEND, the open-label, randomised controlled trial will assess early efficacy of Cymerus MSCs. It builds on the company’s positive pre-clinical study results in ARDS, sepsis and cytokine release syndrome, which are known characteristics of severe Covid-19.

The study will be performed at sites in New South Wales in alliance with the Cerebral Palsy Alliance Research Institute and the Covid-19 Stem Cell Treatment (CSCT) Group investigators.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena